Lelystad, Netherlands, 7 January 2013 - Pepscan Therapeutics, a world leader in protein mimicry technologies for raising anti-GPCR antibodies, today announced a multi-target research agreement with an undisclosed US-based antibody discovery company. Under the agreement Pepscan using its CLIPS platform and other protein mimicry technologies will work with the partner in the discovery of novel antibodies. Under the terms of the agreement, Pepscan will receive R&D funding and could receive payments on the achievement of research and clinical milestones, as well as royalties on sales of products resulting from the collaboration. Financial details of the agreement were not disclosed.
"We are excited to collaborate in this partnership, since we strongly believe that Pepscan's peptide design and protein mimicry technology combined with our partner’s world-class platform for antibody discovery and optimization will yield truly innovative therapeutic products," said Wim Mol, CEO of Pepscan. "We recognize the perfect match of our combined technologies - Pepscan designing and providing tailored peptide immunogens, and our partner applying its state-of-the-art antibody discovery platform. We therefore believe that this agreement only forms the start of a promising and productive relationship between our two companies.”
About Pepscan: Pepscan Therapeutics B.V. is a privately held company based in Lelystad, The Netherlands. Pepscan is using its proprietary CLIPS protein mimicking technology for the development of novel constrained therapeutic peptides and immunogens. Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has various ongoing collaborations with leading pharmaceutical and biotech companies to develop novel therapeutics based on the proprietary CLIPS technology.
About CLIPS: CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of structurally complex protein domains. CLIPS therapeutic peptides have been shown to exert excellent activity and stability. CLIPS peptides are also used as superior immunogens for antibody generation against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins, such as GPCRs.
For further information, please contact:
Wim Mol, CEO - Tel: +31 320 225300